Here’s the problem with every promising new drug that pops out of a lab: There are a million ways to fail before any treatment completes the testing and clinical trials required for commercial approval. Hope springs eternal, but the odds stink. (Boston Globe, 12/24/09)
Two Boston teaching hospitals are stepping up research into cardiovascular disease in separate programs that illustrate the deepening collaboration between academic medical centers and the biopharmaceutical industry. (Boston Globe, 12/23/09)
Swiss drugmaker Roche will not be allowed to sell its anemia drug Mircera in the U.S. until July 2014 under terms of a settlement with Amgen Inc., the companies said Tuesday. (AP, 12/22/09)
Amgen Inc. said Friday a European advisory committee recommended approval of the biotechnology company's osteoporosis drug Prolia, also called denosumab. (AP, 12/18/09)
Aveo Pharmaceuticals Inc., a seven-year-old Cambridge start-up developing cancer drugs, yesterday become the second Massachusetts biotechnology company in four weeks to disclose plans to sell shares in an initial public offering. (Boston Globe, 12/17/09)